Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results
Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint
Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study
Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial
Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results